Costimulation is one of those immunology “gatekeeper” concepts that shows up everywhere on Step exams: why T cells activate (or don’t), how tumors evade immunity, and why checkpoint inhibitors can trigger autoimmune side effects. Here are 3 quick, shareable tips to lock in the highest-yield costimulatory molecules—with mnemonics and one-liners you can recall under time pressure.
Tip 1: B7–CD28 = “Two keys to start the T cell”
The core pairing
- APC (dendritic cell, macrophage, B cell) expresses: B7 (CD80/CD86)
- Naive T cell expresses: CD28
- Signal 1: TCR recognizes peptide–MHC
- Signal 2 (costimulation): B7 binds CD28 → turns on T-cell activation programs
One-liner you can quote on test day
“T cells need antigen + B7–CD28 costimulation; without it, they become anergic.”
Visual mnemonic (quick sketch idea)
Think of the T cell as a car:
- Signal 1 (TCR–MHC) = key in ignition
- Signal 2 (B7–CD28) = turning the key
No turn → no start → anergy.
High-yield facts
- Costimulation drives IL-2 production and clonal expansion (big Step favorite).
- Professional APCs are the ones that reliably provide B7; many other cells can present antigen but can’t fully activate naive T cells.
- Clinical tie-in: Abatacept (CTLA-4–Ig) blocks B7 → used in RA, transplant-related contexts.
Tip 2: CTLA-4 vs CD28 = “Brake beats gas”
The classic “checkpoint” contrast
| Molecule | Location | Binds | Effect | High-yield vibe |
|---|---|---|---|---|
| CD28 | T cell (baseline) | B7 (CD80/86) | Activates T cell | “Gas pedal” |
| CTLA-4 (CD152) | T cell (upregulated after activation; also on Tregs) | B7 (CD80/86) (higher affinity than CD28) | Inhibits T cell activation | “Brake that wins” |
One-liner
“CTLA-4 outcompetes CD28 for B7 and shuts down early T-cell activation.”
Mnemonic device
“CTLA-4 = ‘C’ for Cut-it-off” (competes for Costimulation and Cools T cells).
High-yield facts
- CTLA-4 acts early (priming phase, mainly in lymph nodes) by limiting costimulation.
- Checkpoint inhibitor: Ipilimumab (anti–CTLA-4) → boosts immunity against cancer but can cause immune-related adverse events (colitis, dermatitis, endocrinopathies).
- Tregs use CTLA-4 as part of their suppressive toolkit—classic testable immunoregulation theme.
Tip 3: CD40–CD40L = “License to help” (B cells + macrophages)
The pairing you should never miss
- CD40: on B cells, macrophages, dendritic cells
- CD40L (CD154): on activated CD4+ T helper cells
One-liner
“CD40–CD40L is the ‘help signal’—required for B-cell class switching and for Th1 macrophage activation.”
Mnemonic/visual
“40 = ‘Forty says: FORM a better response’”
- B cells FORM new isotypes (class switching)
- Macrophages FORM stronger killing (activation)
High-yield facts (very testable)
- B cell side: CD40 signaling is crucial for:
- Class switching (IgM → IgG/IgA/IgE)
- Germinal center formation + affinity maturation (classically associated with T-dependent responses)
- Macrophage side (Th1): CD40–CD40L helps macrophages kill intracellular pathogens (paired concept with IFN-γ).
- Disease association: Hyper-IgM syndrome (X-linked) due to CD40L deficiency
- Findings: high IgM, low IgG/IgA/IgE
- Recurrent pyogenic/opportunistic infections (classically includes Pneumocystis and Cryptosporidium risk)
- Absent germinal centers in lymph nodes
Rapid-fire recap (shareable)
- B7 (CD80/86) on APC + CD28 on T cell → IL-2, proliferation; no costimulation → anergy
- CTLA-4 binds B7 harder than CD28 → turns T cells off (checkpoint; target of ipilimumab)
- CD40 (B cell/macrophage) + CD40L (activated Th cell) → class switching + macrophage activation (CD40L defect → Hyper-IgM)